THNR vs WDNA: Holdings Overlap & Returns
Over the year to Nov 13, 2026, THNR returned +6.7% to WDNA's +43.3%; 16% of their weight is in the same names.
- Return gap
- +36.6 pts1 year to Nov 13, 2026: WDNA ahead, total return
- Fee gap
- 0.14 ptsA year: THNR 0.59%, WDNA 0.45%, per filings dated Jan 28, 2026 and Oct 28, 2026
- Overlap
- 16%Share of the two books held in common, holdings dated Nov 13, 2026 and Jun 30, 2026
- Net flow
- –Needs daily flows for both funds
Compare two other funds
Growth of 100
Drawn from the numbers on this page. Growth of 100, both funds, distributions reinvested
THNR +6.7%, WDNA +43.3%: WDNA +36.6 pts ahead, 1 year, Nov 13, 2025 to Nov 13, 2026.
ShareUse this comparison
No client brief for this pair: the two funds' holdings are dated 136 days apart.
Cost to trade
Hypothetical. A $10,000 order in THNR costs about $14.00 one way and $28.00 in and out, at a median spread of 0.28%. The 0.28% spread is THNR’s 30-day median, from Amplify (fund page).
Fees over time
Hypothetical. $10,000 in THNR for 10 years at 0.59% a year costs about $972 in fees and lost growth; WDNA at 0.45% would cost $746. Assumes 6% a year before fees, a sample rate, not a forecast.
How each fund moved
46% of THNR's weight is in S&P 500 companies and 54% is outside the index. Holdings as of Nov 13, 2026.
26% of WDNA's weight is in S&P 500 companies and 74% is outside the index. Holdings as of Jun 30, 2026.
Key numbers
WDNA costs 0.14 points a year less; their one-year returns differ by 36.6 points.
Pair scorecard
Open the table
Points (pts) are percentage points.
| Total return, 1 year | +6.7% | +43.3% |
|---|---|---|
| Below its all-time high | 6.3%, high on Aug 25, 2026 | 13.9%, high on Sep 2, 2021 |
| What it tracks | Healthcare innovation and GLP-1 | Healthcare innovation and GLP-1 |
| Expense ratio | 0.59% | 0.45% |
| Net assets, THNR as of Nov 12, 2026 and WDNA as of Jun 30, 2026 | $5.2m | $2.7m |
| Active share vs the S&P 500 | 96% | 95% |
| Holdings in common | 16% |
The numbers behind it
Net assets: $5.2m on Nov 12, 2026 for Amplify Weight Loss Drug & Treatment ETF, and $2.7m on Jun 30, 2026 for WisdomTree BioRevolution Fund.
Holdings in common uses holdings dated Jun 30, 2026 and Nov 13, 2026.
What they share
By the books each fund has filed, THNR and WDNA hold 16% of their money in the same securities at the same weight. Holdings dated Jun 30, 2026 and Nov 13, 2026.
half
16% in common
Held in common
Show all 10 holdings
| Eli Lilly & Co | 12.10% | 4.08% |
| Structure Therapeutics Inc | 2.03% | 2.12% |
| AstraZeneca PLC | 5.79% | 1.83% |
| Amgen Inc | 6.11% | 1.54% |
| Gilead Sciences Inc | 5.66% | 1.51% |
| Arrowhead Pharmaceuticals Inc | 2.81% | 1.47% |
| Pfizer Inc | 5.24% | 1.34% |
| Viking Therapeutics Inc | 4.43% | 0.93% |
| Merck & Co Inc | 4.98% | 0.70% |
| Regeneron Pharmaceuticals Inc | 6.05% | 0.54% |
Only in THNR
Show all 8 holdings
| Novo Nordisk A/S | 8.89% |
| Roche Holding AG | 5.68% |
| AbbVie Inc | 5.65% |
| Chugai Pharmaceutical Co Ltd | 5.17% |
| CSPC Pharmaceutical Group Ltd | 4.44% |
| Innovent Biologics Inc | 4.35% |
| Zealand Pharma A/S | 3.29% |
| Hanmi Pharm Co Ltd | 3.19% |
Only in WDNA
Show all 8 holdings
| TWIST BIOSCIENCE CORP | 5.95% |
| MODERNA INC | 4.14% |
| JOHNSON & JOHNSON | 2.97% |
| UNITED THERAPEUTICS CORP | 2.45% |
| NATERA INC | 2.32% |
| TEMPUS AI INC | 2.28% |
| IMMUNOME INC | 2.26% |
| STOKE THERAPEUTICS INC | 2.09% |
Side by side
Open the table
| Fund | Amplify Weight Loss Drug & Treatment ETF · Holds 21 stocks in healthcare innovation and GLP-1, 46% of its weight in S&P 500 companies | WisdomTree BioRevolution Fund · Holds 80 stocks in healthcare innovation and GLP-1, 26% of its weight in S&P 500 companies |
| Issuer | Amplify | WisdomTree |
| Theme | Healthcare innovation and GLP-1 | Healthcare innovation and GLP-1 |
| In the S&P 500 | 45.8% | 25.9% |
| Active share vs the S&P 500 | 96.5% | 95.3% |
| In the Nasdaq-100 | 17.8% | 5.2% |
| Holdings | 21 | 80 |
| Top ten, share of the fund | 66.3% | 30.7% |
| Expense ratio | 0.59% | 0.45% |
| Fee for the differing part | 0.61% | 0.47% |
| Total return, 1 year | +6.7% | +43.3% |
| vs its benchmark | not measured | not measured |
| Below its high | −6.3% | −13.9% |
| Net assets, THNR as of Nov 12, 2026 and WDNA as of Jun 30, 2026 | $5.2m | $2.7m |
As of Nov 13, 2026. Source: ETFIQ.
Window by window
Open the table
| 3 months | −0.1% | +6.8% |
|---|---|---|
| 6 months | +7.0% | +30.6% |
| 1 year | +6.7% | +43.3% |
| 3 years | – | +62.5% |
| Since launch (Not the same days: THNR May 2024 · WDNA Jun 2021) | +5.6% | −3.7% |
– means no data for this window.
From May 2024 to Nov 2026, WDNA returned more: +49.2% to +5.9%. THNR swung less: 20.1% to 26.2%. THNR fell slightly less at its worst: −30.0% to −30.7%.
Full scorecard
Open the table
| Total return | +5.9% | +49.2% | WDNA | Price change plus distributions, reinvested. |
| Annualized | +2.3% | +17.7% | WDNA | Total return as a yearly rate. |
| Price return | +3.2% | +41.8% | WDNA | Price change alone, distributions left out. |
| Volatility | 20.1% | 26.2% | THNR | Spread of weekly returns, annualized. Lower is steadier. |
| Downside deviation | 14.2% | 17.2% | THNR | Like volatility, counting only weeks below the Treasury bill rate. |
| Max drawdown | −30.0% | −30.7% | THNR (slight) | Deepest fall from a high to the low after it. |
| Sharpe | 0.01 | 0.59 | WDNA | Return above Treasury bills per unit of volatility. |
| Sortino | 0.01 | 0.90 | WDNA | Return above Treasury bills per unit of downside deviation. |
| Calmar | 0.08 | 0.58 | WDNA | Annualized return divided by the max drawdown. |
More
Computed by ETFIQ from Tiingo daily prices and ETFIQ's distribution records, 128 weekly returns. Cash rate: the 13-week Treasury bill.
About THNR
By weight, 46% of THNR's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 96%. The top ten holdings are 66% of the fund across 21 positions, as published by its issuer for Nov 13, 2026.
More
Over the year to Nov 13, 2026 the fund returned +6.7% with distributions reinvested. It sits 6.3% below its all-time high of Aug 25, 2026.
About WDNA
By weight, 26% of WDNA's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 95%. The top ten holdings are 31% of the fund across 80 positions, as filed for Jun 30, 2026.
More
Over the year to Nov 13, 2026 the fund returned +43.3% with distributions reinvested. It sits 13.9% below its all-time high of Sep 2, 2021.
16% of the two portfolios are the same securities at the same weight.
Questions people ask
Do THNR and WDNA hold the same stocks?
By their latest filings, 16% of their books are the same securities at the same weight. Overlap is the sum of the smaller weight of every security they share.
Other comparisons
Sources
More
Links are sources, not endorsements. A comparison is not a recommendation.
Copy and cite
Cite this pageCitation, APA and Markdown
ETFIQ, THNR against WDNA, data as of Nov 13, 2026. https://etfiq.com/compare/themes/thnr-vs-wdna
ETFIQ. (Nov 13, 2026). THNR against WDNA. Retrieved from https://etfiq.com/compare/themes/thnr-vs-wdna
[THNR against WDNA (ETFIQ, Nov 13, 2026)](https://etfiq.com/compare/themes/thnr-vs-wdna)
Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.